Navigation Links
ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
Date:12/4/2007

>

The Phase IIa MIVI-IIT trial reported today was a sham injection controlled study in which patients were assigned to receive either 75ug or 125ug of microplasmin. A total of 30 patients across Europe were recruited to the study, of which 24 received microplasmin therapy while 6 received the sham injection. The trial showed clear benefits from therapy with 9 of the 24 microplasmin treated patients seeing resolution of their vitreomacular traction (including macular hole closure in 2 of the 4 macular hole cases) without the need for vitrectomy. In contrast, none of the 6 sham injected patients had resolution of their vitreomacular traction (including two patients with macular hole). The trial also showed that microplasmin therapy was safe and well tolerated. Given the excellent safety of microplasmin in the trial to-date, it has been decided to recruit a further 15 patients (12 treated and 3 sham) to evaluate a higher 175ug dose of the product to see if it will produce even better clinical outcomes.

Professor Peter Stalmans, the study's principal investigator, commented: "The results from the study that I will present at the ASRS meeting today clearly indicate the potential for microplasmin to become a more convenient, less invasive, hence more patient friendly treatment for vitreomacular traction. The fact that we have been able to clearly show that microplasmin can achieve clinically important outcomes such as traction release and macular hole closure without surgery augurs well for the future development of this novel treatment."

Prof. Desire Collen, CEO of ThromboGenics, commenting on today's results said: "The results of the microplasmin trial that we have announced today clearly show the drug's potential to treat a range of back of the eye diseases. The clinical benefits that we have seen in this study in conjunction with its excellent safety profile provide us with sound reasons for pushing ahead with the further clinical development of microp
'/>"/>

SOURCE ThromboGenics NV
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
2. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
3. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
4. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
5. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
6. Touching 418 Billion Lives, Hepatitis Still Presents Significant Threat to Global Health
7. Touching 418 Million Lives, Hepatitis Still Presents Significant Threat to Global Health
8. Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting
9. Sangamo BioSciences Presents Data Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic
10. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
11. Arpida Presents Preclinical Data on AR-2474 at ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... Innovation is more urgent than ever. Radical ... the world and transforming global markets in industry ... health care, disruption is constantly underway. , As ... shake the foundations of established business models, large-scale ... survive the next wave of mega-change. , This ...
(Date:2/26/2015)... , Feb. 26, 2015  Dyadic International, Inc. ... patented and proprietary technologies are used to develop, ... the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme ... financial results for year ending December 31, 2014 ... and will host a conference call that day ...
(Date:2/26/2015)... , Feb. 26, 2015 Tauriga Sciences, Inc. ... company with interests in the natural wellness sector and ... today that its products will be featured at the ... Partners, 27 th Annual Growth Stock Conference on ... at 1 Ritz Carlton Drive, Dana Point ...
(Date:2/26/2015)... -- Spark Therapeutics (NASDAQ: ONCE ) announced today ... the Cowen and Company Health Care Conference on Wednesday, ... Boston Marriott Copley Place. To access the ... Cowen conference, please visit the "Upcoming Events" section within ... website at www.sparktx.com .  A replay of the ...
Breaking Biology Technology:One Million Acts of Innovation Canada Creates Partnership with The Economist Events’ Innovation Forum 2Dyadic International To Announce Fourth Quarter 2014 Financial Results And Host Conference Call On Wednesday, March 11, 2015 2Dyadic International To Announce Fourth Quarter 2014 Financial Results And Host Conference Call On Wednesday, March 11, 2015 3SEC Compliance Featuring Products From Tauriga Sciences, Inc. at ROTH Capital Conference 2SEC Compliance Featuring Products From Tauriga Sciences, Inc. at ROTH Capital Conference 3SEC Compliance Featuring Products From Tauriga Sciences, Inc. at ROTH Capital Conference 4Spark Therapeutics to Participate in the 35th Annual Cowen and Company Health Care Conference 2
... (Amex: IMM ) will have an investor conference ... to discuss its financial results for the quarter,ended December ... Company,s,scientific and clinical progress. Investors and interested parties in ... (888) 338-8374 and callers,outside the U.S. should call (706) ...
... 6 Mediware Information,Systems, Inc. (Nasdaq: MEDW ) ... repurchase of up to $4 million of the company,s ... and Chief Executive Officer or Chief,Financial Officer of the ... obligation to repurchase shares under the program., Commenting, ...
... ... Services Network, POWAY, Calif., Feb. 6 ... diagnostic imaging systems,and services to physicians, offices, hospitals and imaging centers, ... American,Nuclear Medicine Equipment Product Line Strategy Award., Travis Chong, research ...
Cached Biology Technology:Immtech Investor Conference Call Scheduled for February 11, 2008 2Mediware Board Authorizes $4 Million Stock Buyback 2Digirad Corporation to Receive Frost & Sullivan 2007 North American Award for Product Strategy 2Digirad Corporation to Receive Frost & Sullivan 2007 North American Award for Product Strategy 3
(Date:2/5/2015)... OXFORD, Conn. , Jan. 28, 2015 ... ("NXT-ID" or the "Company"), a biometric authentication company focused ... present at the upcoming RedChip Global Online CEO Conference ... Gino Pereira , CEO of ... discussing its lead product, the Wocket smart wallet and ...
(Date:1/22/2015)... CHICAGO , Jan. 9, 2015 Valid S.A. ("Company") ... the market in general the State of Washington,s ... contract for a new enrollment and central issuance system for ... The project planning and development will start ...
(Date:1/22/2015)... 16, 2015  A man-made form of insulin delivered by ... capabilities in adults with mild cognitive impairment and Alzheimer,s ... researchers at Wake Forest Baptist Medical Center. ... mild cognitive impairment (MCI) or mild to moderate Alzheimer,s ...
Breaking Biology News(10 mins):CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3Valid USA Signs Contract For Washington Driver's License Issuance 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3
... terms of diversity and sheer numbers, the microbes occupying ... inhabiting the Earth. Numbering in the tens of trillions ... microbiome, as it,s called, helps the body perform a ... understood. How this microbial mlange may be ...
... Toxoplasma gondii , a common parasite of people and ... report will appear online on January 19th in The ... response spares T. gondii -infected hosts from deadly infectionan ... survival of the host to ensure its own transmission. But ...
... MobileCop UnitsWALL, N.J., Jan. 13 ... leader in finger-based biometric identification and wireless public ... Lincoln, NE Police Department. The award was ... (PSIC) grant from the Department of Homeland Security ...
Cached Biology News:Our microbes, ourselves 2Our microbes, ourselves 3Our microbes, ourselves 4BIO-key(R) Mobile Data and Messaging Solutions Link Nebraska Law Enforcement Agencies 2BIO-key(R) Mobile Data and Messaging Solutions Link Nebraska Law Enforcement Agencies 3
Neuropilin-2 Purified Anti-Rat clone 54, Isotype Mouse IgG 1 , 150 µg Consult technical datasheet for details....
CBF-B (G-2)...
HSV-2 gD (0191)...
... Dynabeads Epoxy (4.5 m). Hydrophobic naked ... Ideal for coupling of antibodies for cell ... coupling with covalent binding of primary amine ... (SH)) occurring within 16-20 hours. Coupling reactions ...
Biology Products: